Schweizerischer Nationalfonds / Fonds national suisse
Novel approaches to health care
mehr
Storys zum Thema Medizinische Forschung
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Largest decentralised study of its kind shows high levels of engagement with Huma's study app
London (ots/PRNewswire) - - More than 90% of 2,524 participants invited to join a fully virtual COVID-19 study, run by Cambridge researchers, downloaded and registered on the study app1 - Around 75% of participants completed digital biomarker assessments such as resting heart rate, temperature and oxygen saturation at least once per week1 - Participants were aged 45 - ...
mehrMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
mehrHuma to provide best-in-class digital clinical trials solutions through landmark acquisition of Alcedis
London and Frankfurt, Germany (ots/PRNewswire) - - Acquisition combines award-winning digital health platform with global clinical research expertise acquired over 25 years - Creates new and advanced digital solutions across all phases of clinical trials - Accelerates patient recruitment and the development of new ...
mehrREVEAL GENOMICS PRESENTS THE LATEST HER2DX® DATA IN HER2+ BREAST CANCER AT SABCS 2022
San Antonio (ots/PRNewswire) - - The HER2DX® risk score predicted long-term survival outcomes in clinically low-risk patients in APT and ATEMPT clinical trials. - The HER2DX® pCR score predicted response to chemotherapy in combination with trastuzumab and pertuzumab in DAPHNe and GOM clinical trials. - HER2DX®️ is the first genomic test in the world specialized in ...
mehrLUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference ...
mehr
Cannbit-Tikun Olam begins cannabis extracts export from Israel to Europe at the largest commercial quantity to date
Tel Aviv, Israel (ots/PRNewswire) - Cannbit-Tikun Olam Israel(TASE:TKUN), Israel's medical cannabis pioneer, today announced that the first commercial shipment of medical cannabis extracts produced by the company was making its way to Germany. It marks the largest volume of cannabis extracts exported from Israel to ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Improving the efficacy of antibiotics and curbing resistance
Bern (ots) - New findings from NRP 72, financed by the Swiss National Science Foundation, are helping to curb antibiotic resistance. In the field of new antibiotics, however, structures needed for translating results into practice are lacking. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. As antibiotics lose their efficacy, infections that were once easy to treat can give rise to fatal ...
mehrTauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
mehrTauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
mehrDebiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data
Boston, USA and Lausanne, Switzerland (ots) - - SaaS Platform Provides Missing Link in Clinical Trial Data Collection, Securely Automating Real-Time Transfer of Up-to-Date Patient Data Directly from EHRs to EDC Systems - Technology Brings New Levels of Speed, Quality and Efficiency to Clinical Trial Data Collection ...
mehrForging a healthier future through research: McGill University launches new Institute of Genomic Medicine
Montreal (ots/PRNewswire) - Landmark donation from alumnus Dr. Victor Phillip Dahdaleh will accelerate advances in global health using genomic medicine to inform patient diagnosis and care A landmark donation to support McGill University's renowned genomics research and education programs from UK-based alumnus and ...
mehr
Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals
New York (ots/PRNewswire) - - Synapse Medicine clinical decision support technology analyzes drug-related risks based on each patient's clinical characteristics and will be studied for its impact on inpatient pharmacist efficacy and efficiency. - The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals' current EPIC ...
mehrDEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
mehrGuerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
Villepinte, France (ots/PRNewswire) - - FDA approval of Elucirem™ (NDA 216986) was granted after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies. - In the approved indications, a ...
mehrThe fourth ORBIS School enhancing international collaboration on pharmaceutical innovations was held in Prague
Prague (ots/PRNewswire) - Between 7th and 9th September, the fourth ORBIS School was held in Prague. The event was co-hosted by Zentiva in close collaboration with the German company Physiolution and the University of Chemistry and Technology in Prague. Many various lectures and workshops were held during these ...
mehrDebiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical ...
mehrDebiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Lausanne (ots) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm ...
mehr
Almirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials
Barcelona, Spain (ots/PRNewswire) - - New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity - Results suggest less frequent, every four week dosing of lebrikizumab provided ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Broad-based Swiss Covid-19 research
Bern (ots) - During the coronavirus pandemic, the Swiss National Science Foundation (SNSF) supported a total of 114 Covid-19 research projects, for which it used funding of over CHF 45 million. In the National Research Programme "Covid-19" (NRP 78), around 200 researchers are working in 28 projects with a total budget of CHF 20 million. Another research programme on Covid-19 is about to start. It was the first time the ...
mehrMenarini Silicon Biosystems; DIESSE
Menarini Silicon Biosystems and DIESSE announced strategic partnership to distribute CHORUS TRIO in North America
Chicago (ots/PRNewswire) - The commercial agreement to promote and sell CHORUS TRIO immunometric assay solutions in the U.S. Market was announced jointly by the two companies during the AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago. Menarini Silicon Biosystems Inc, a US company part of the Menarini ...
mehrGrünenthal, Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research
Aachen (ots) - Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, ...
mehrNeuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal, Shows Greater Improvement of Symptoms
Dublin (ots/PRNewswire) - - Second large-scale trial shows greater reduction in tinnitus symptom severity using bimodal neuromodulation device, Lenire® - 91% of treatment compliant participants experienced improvement in tinnitus symptoms that sustained 12 months after treatment - 87.8% said they would recommend ...
mehrProfessor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer
Copenhagen (ots/PRNewswire) - MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022. Professor Lars Iversen will be a key member of the Executive Team at MC2 ...
mehr
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
Singapore (ots/PRNewswire) - - LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research - Safety profile is favourable and consistent with previous HMTM studies - TauRx will now pursue ...
mehrFilterlex Medical Announces Positive Results from A First-In-Human Study for the CAPTIS® Full-Body Embolic Protection Device
Caesarea, Israel (ots/PRNewswire) - Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications. Filterlex Medical Ltd., a cardiovascular medical device startup, announced today results from a first-in-human (FIH) study demonstrating the ...
mehrPOCARED Diagnostics; European Investment Bank
Pocared Diagnostics, an Israeli rapid infectious diseases diagnostics leader, secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system
Rehovot, Israel (ots/PRNewswire) - - First EIB support for medtech investment in Israel - Financing to accelerate development of rapid testing system to improve infectious disease diagnosis and antibiotics stewardship - Automated phenotypic testing, revolutionizing infectious diseases diagnostics from sample to ...
mehrSeries A financing round lays foundation for international growth of digital cancer therapeutics Mika
Berlin/Lausanne/Barcelona/Munich (ots) - New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika - an app-based DTx platform empowering people affected by cancer. Berlin-based digital health company Fosanis, the ...
mehrREVEAL GENOMICS®️ ANNOUNCES RESEARCH COLLABORATION IN HER2+ BREAST CANCER
Barcelona, Spain (ots/PRNewswire) - - The agreement with Dana-Farber Cancer Institute consists of using HER2DX®️ to analyze tumor samples from more than 500 patients with early-stage HER2+ breast cancer across three clinical trials (APT, ATEMPT, and DAPHNE). - The three completed studies were essential in establishing new anti-HER2-based treatment strategies for ...
mehrTauRx's late-stage clinical trial reaches new milestone
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed ...
mehr
Vorherige12345Nächste